로딩 중...
52주 최고가 대비 83.9% 위치
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $26.32B | $28.19B | $33.42B | $36.75B |
| 영업이익 | - | $9.57B | $7.90B | $7.26B | $9.08B |
| 당기순이익 | - | $6.55B | $6.72B | $4.09B | $7.71B |
| 잉여현금흐름 (FCF) | - | $8.79B | $7.36B | $10.39B | $8.10B |
| 수익성 비율 | |||||
| 영업이익률 | - | 36.3% | 28.0% | 21.7% | 24.7% |
| 순이익률 | - | 24.9% | 23.8% | 12.2% | 21.0% |
| ROE (자기자본이익률) | - | 179.0% | 107.8% | 69.6% | 89.1% |
| ROA (자산이익률) | - | 10.1% | 6.9% | 4.5% | 8.5% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 7.1% | 18.6% | 10.0% |
| EPS 성장률 (YoY) | - | - | 3.1% | -39.5% | 88.2% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | 18.7x | 23.3x | 36.0x | 23.7x |
| PBR (주가순자산배수) | - | 33.3x | 25.2x | 25.0x | 21.0x |
| PSR (주가매출배수) | - | 4.6x | 5.6x | 4.4x | 4.9x |
| FCF Yield | - | 7.2% | 4.7% | 7.1% | 4.5% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 10.64 | 10.37 | 10.23 | 6.31 |
| 유동비율 | - | 1.41 | 1.65 | 1.26 | 1.14 |
MOLINA HEALTHCARE INC
$179.86
$9.4B